Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer

vanBasten, Jpa; Hoekstra, HJ; Vandriel, Mf; Sleijfer, Dt; Droste, J. H. J.; Koops, H. Schraffordt

doi:10.1007/bf02303585

Cited by 32 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Discordant histology and advanced clinical stage significantly effected OS and DSS rates in the synchronous group. In contrast, survival rates of men with metachronous tumours were no worse than those with unilateral tumours, which range from 95% to 99%, according to previously published data [68–70]. The prognosis was good for both seminomatous and non‐seminomatous tumours.…”

Section: Discussionsupporting

confidence: 51%

Bilateral testicular germ cell tumours: a systematic review

Zéqui¹,

Costa²,

Santana³

et al. 2012

BJU International

View full text Add to dashboard Cite

What's known on the subject? and What does the study add? Bilateral testicular germ cell tumours (BTGCTs) are rare neoplasms. Most previously published studies consist of case reports or small retrospective case series. Little is known about their epidemiological and clinicopathological characteristics. BTGCT corresponded to 1.82% of testicular tumours. Metachronous disease was about twice as frequent as synchronous disease. The primary tumour histology, chemotherapy use and the interval between metachronous tumours influenced the histology of the second tumour. Overall, synchronous tumours were associated with more advanced disease and presented less favourable survival rates than metachronous tumours. Testicular cancer is the most common tumour in young men. It is known that a second primary contralateral testis tumour may occur in up to 5% of men with a proior tumour. About 35% of these men present with synchronous tumours, and 65% present with metachronous tumours. However there is little data about bilateral testicular germ cell tumours (BTGCT) in the literature and the most published articles are case reports on a small series of men, which makes it difficult to draw conclusions about therapeutic strategies for the treatment of BTGCTs. In fact, current guidelines for the treatment of testicular cancer contain little information related to bilateral disease. Therefore, the aim of our study is to provide a broad overview of BTGCT and to update data focusing on incidence, pathological features, and clinical outcomes of men with BTGCTs. Thus, an extensive review containing 94 studies and more than 50,000 patients was conducted.

show abstract

Section: Discussionsupporting

confidence: 51%

Bilateral testicular germ cell tumours: a systematic review

Zéqui¹,

Costa²,

Santana³

et al. 2012

BJU International

View full text Add to dashboard Cite

show abstract

“…[6][7][8][9]12,13 Recent years' publications have addressed whether modern cisplatin-based chemotherapy might influence the effect of risk factors, but these results have also been inconclusive. 8,10,12,[14][15][16] Our hypothesis is that cisplatin-based chemotherapy, available since 1980 for patients with TGCT in Norway, reduces the risk of a metachronous contralateral TGCT. And any risk-reducing impact would be more evident for patients presenting with metastatic versus localized disease, as nearly all of the former ones have received such treatment, compared to only 20-25% in the latter group.…”

Section: Introductionmentioning

confidence: 99%

Risk of metachronous contralateral testicular germ cell tumors: A population‐based study of 7,102 Norwegian patients (1953–2007)

Andreassen

Grotmol

Cvancarova

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

The purpose of the study was to identify overall incidence and risk of developing a metachronous contralateral testicular germ cell tumor (TGCT) and compare the risk for patients treated before and after 1980 (cisplatin became available for patients with metastatic TGCT). Our hypothesis was that the risk of metachronous TCGT would be reduced for patients with metastatic disease diagnosed after 1980. We included 7,102 men with unilateral TGCT, recorded in the Cancer Registry of Norway. Allowing for competing risk, cumulative incidence and adjusted hazard ratio (HR) were estimated for different subgroups, and the diagnostic periods 1953 -1979 (I) and 1980. Relative risks were assessed by standardized incidence ratio (SIR). In Period I and Period II, 38 and 137 males, respectively, were diagnosed with metachronous contralateral TGCT. Corresponding 20-year cumulative incidences were 1.9% and 3.9%. In Period II, risk of a second TGCT was halved [HR 5 0.5, 95% confidence interval (95% CI) 5 0.33-0.77] for patients with metastatic compared to localized disease. For patients presenting with localized and metastatic disease, the SIRs for Period I were 14.6 (95% CI 5 9.6-21.2) and 25.3 (95% CI 5 12.1-46.5), respectively. In Period II, the corresponding numbers were 19.0 (95% CI 5 15.6-22.9) and 9.8 (95% CI 5 6.4-14.5). In conclusion, the risk of metachronous contralateral TGCT was halved for patients with metastatic compared to localized disease in Period II, whereas this protective effect of extent of disease lacked significance for Period I. These findings support our hypothesis that cisplatin-based chemotherapy reduced the risk of a second TGCT for patients with metastatic TGCT diagnosed after 1980.

show abstract

“…Several other studies reported a higher CTGCT risk for seminoma compared with non-seminoma TGCT patients, which may reflect differences in treatment (Che et al , 2002; Theodore et al , 2004; Fosså et al , 2005). However, few studies directly evaluated the effect of TGCT treatment on CTGCT risk, with controversial results (van Basten et al , 1997; Wanderås et al , 1997). …”

mentioning

confidence: 99%

Risk and prognostic significance of metachronous contralateral testicular germ cell tumours

et al. 2012

View full text Add to dashboard Cite

Background:Testicular germ cell tumour (TGCT) patients are at increased risk of developing a contralateral testicular germ cell tumour (CTGCT). It is unclear whether TGCT treatment affects CTGCT risk.Methods:The risk of developing a metachronous CTGCT (a CTGCT diagnosed ⩾6 months after a primary TGCT) and its impact on patient's prognosis was assessed in a nationwide cohort comprising 3749 TGCT patients treated in the Netherlands during 1965–1995. Standardised incidence ratios (SIRs), comparing CTGCT incidence with TGCT incidence in the general population, and cumulative CTGCT incidence were estimated and CTGCT risk factors assessed, accounting for competing risks.Results:Median follow-up was 18.5 years. Seventy-seven metachronous CTGCTs were diagnosed. The SIR for metachronous CTGCTs was 17.6 (95% confidence interval (95% CI) 13.9–22.0). Standardised incidence ratios remained elevated for up to 20 years, while the 20-year cumulative incidence was 2.2% (95% CI 1.8–2.8%). Platinum-based chemotherapy was associated with a lower CTGCT risk among non-seminoma patients (hazard ratio 0.37, 95% CI 0.18–0.72). The CTGCT patients had a 2.3-fold (95% CI 1.3–4.1) increased risk to develop a subsequent non-TGCT cancer and, consequently, a 1.8-fold (95% CI 1.1–2.9) higher risk of death than patients without a CTGCT.Conclusion:The TGCT patients remain at increased risk of a CTGCT for up to 20 years. Treatment with platinum-based chemotherapy reduces this risk.

show abstract

Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer

Cited by 32 publications

References 35 publications

Bilateral testicular germ cell tumours: a systematic review

Bilateral testicular germ cell tumours: a systematic review

Risk of metachronous contralateral testicular germ cell tumors: A population‐based study of 7,102 Norwegian patients (1953–2007)

Risk and prognostic significance of metachronous contralateral testicular germ cell tumours

Contact Info

Product

Resources

About